A Multicenter, Randomized, Double-blind, Placebo controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction
This Phase 2 study is about testing the safety of the investigational oral drug IW-1973 (Praliciguat), compared to a placebo, and its effect on the ability to exercise after being taken for 12 weeks. In addition, explore the effect of the oral IW-1973 on the heart function, quality of life, health status, biomarkers and pharmacokinetics of the oral IW-1973 for 12 weeks.
PI: Dr. Ilia Halatchev
Study Coordinator: Marie White
This study is now closed to enrollment.